A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314
Recruiting
99 years or below
All
1 Location
Brief description of study
This is a prospective, observational study designed to evaluate the long-term safety and efficacy of RGX-314. Eligible participants are those who were previously enrolled in a clinical study in which they received a single subretinal administration of RGX-314 (IRB #827859). Participants will be followed for up to 5 years post-RGX-314 administration (inclusive of the parent study).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
Updated on
12 Apr 2023.
Study ID: 833581